Abstract
Congenital factor X (FX) deficiency with an estimated incidence of 1:1,000,000 is one of the rarest and most severe bleeding disorders that is inherited in autosomal recessive manner. Acquired form of FX deficiency is also rare and usually occurs in relation with AL amyloidosis. The most frequent bleeding diathesis in FX deficiency is mucosal bleedings such as epistaxis, gum bleeding, easy bruising, and menorrhagia. Spontaneous major bleedings such as hemarthrosis, hematoma, gastrointestinal (GI) and central nervous system (CNS) bleeding usually occur in the severely affected individuals. The patients with less severe FX deficiency may bleed after hemostatic challenges including surgery or trauma. FX deficiency is suspected following abnormal bleeding history with prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT) that will correct with a 1:1 mix with normal plasma. Then diagnosis should be confirmed by specific tests including antigenic (FX:Ag) and functional (FX:C) assays. Treatment of FX deficiency is based on replacement therapy by fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC). A single-factor FX concentrate produced from human plasma (pdFX) recently was approved by FDA.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Uprichard J, Perry DJ. Factor X deficiency. Blood Rev. 2002;16(2):97–110.
Brown D, Kouides P. Diagnosis and treatment of inherited factor X deficiency. Haemophilia. 2008;14(6):1176–82.
Lee CA, Berntorp EE, Keith Hoots W. Textbook of hemophilia. Oxford: Blackwell; 2010. [cited 2017 2017].
Peyvandi F, Menegatti M. Inherited deficiencies of coagulation factors II, V, V+VIII, VII, X, XI, and XIII. In: Williams hematology. 9th ed. New York: McGraw-Hill; 2016. p. 40.
Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104(5):1243–52.
Karimi M, Menegatti M, Afrasiabi A, Sarikhani S, Peyvandi F. Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency. Haematologica. 2008;93(6):934–8.
Perry D. Factor X and its deficiency states. Haemophilia. 1997;3(3):159–72.
Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med. 2004;10(1-6):6.
Girolami A, Vettore S, Scarparo P, Lombardi A. Persistent validity of a classification of congenital factor X defects based on clotting, chromogenic and immunological assays even in the molecular biology era. Haemophilia. 2011;17(1):17–20.
Lee G, DUAN-PORTER W, Metjian A. Acquired, non-amyloid related factor X deficiency: review of the literature. Haemophilia. 2012;18(5):655–63.
Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015. https://doi.org/10.1182/blood-2014-08-532820.
Girolami A, Scarparo P, Scandellari R, Allemand E. Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation. Am J Hematol. 2008;83(8):668–71.
Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost. 2009;35:407.
Herrmann F, Auerswald G, RUIZ-SAEZ A, Navarrete M, Pollmann H, Lopaciuk S, et al. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia. 2006;12(5):479–89.
Peyvandi F, Mannucci P, Lak M, Abdoullahi M, Zeinali S, Sharifian R, et al. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol. 1998;102(2):626–8.
Acharya S, Coughlin A, Dimichele DM. Rare bleeding disorder registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost. 2004;2(2):248–56.
Thompson CA, Kyle R, Gertz M, Heit J, Pruthi R, Pardanani A. Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010;85(3):171–3.
Vaidya K, Arnott C, Biscoe A, Eggleton S, Brighton T. Differential diagnosis and therapeutic limitations in a rare case of acquired factor X deficiency. Case Rep Intern Med. 2015;2(4):55.
Nance D, Josephson N, Paulyson-Nunez K, James A. Factor X deficiency and pregnancy: preconception counselling and therapeutic options. Haemophilia. 2012;18(3):e277.
Mariani G, Herrmann F, Schulman S, Batorova A, Wulff K, Etro D, et al. Thrombosis in inherited factor VII deficiency. J Thromb Haemost. 2003;1(10):2153–8.
Genotype of patients with factor X deficiency. 2011. http://c.ymcdn.com/sites/www.isth.org/resource/resmgr/publications/fx_mutations-2011.pdf?hhSearchTerms=%22coagulation+and+factor+and+X%22
Mota L, Shetty S, Idicula-Thomas S, Ghosh K. Molecular basis of factor X deficiency cases from India. Haemophilia. 2010;16(4):693–7.
Herrmann FH, Navarette M, Salazar-Sanchez L, Carillo JM, Auerswald G, Wulff K. Homozygous factor X gene mutations Gly380Arg and Tyr163delAT are associated with perinatal intracranial hemorrhage. J Pediatr. 2005;146(1):128–30.
Borhany M, Shamsi T, Moiz B, Hasan K, Hashmi KZ, Ayyub M, et al. Guidelines on the laboratory diagnosis of congenital bleeding disorders in Pakistan. JPMA J Pak Med Assoc. 2012;62(5):477.
Kaushansky K, Williams WJ, Joseph W. Williams hematology. New York: McGraw-Hill Medical; 2010.
Markland FS. Snake venoms and the hemostatic system. Toxicon. 1998;36(12):1749–800.
Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost. 2008;34:58.
Austin S, Brindley C, Kavakli K, Norton M, Shapiro A. Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency. Haemophilia. 2016;22(3):426–32.
Shapiro A. Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety. Expert Opin Drug Metab Toxicol. 2017;13(1):97–104.
Bolton-Maggs P, Perry D, Chalmers E, Parapia L, Wilde J, Williams M, et al. The rare coagulation disorders–review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia. 2004;10(5):593–628.
io Products Laboratory Receives FDA approval for Coagadex® (Coagulation Factor X, Human). 2015. http://www.businesswire.com/news/home/20151021005989/en/Bio-Products-Laboratory-Receives-FDA-approval-Coagadex%C2%AE
FDA Approves Coagadex®. First factor X concentrate. 2015. https://www.hemophilia.org/Newsroom/Medical-News/FDA-Approves-Coagadex-First-Factor-X-Concentrate
Mumford AD, Ackroyd S, Alikhan R, Bowles L, Chowdary P, Grainger J, et al. Guideline for the diagnosis and management of the rare coagulation disorders. Br J Haematol. 2014;167(3):304–26.
Tabibian S, Motlagh H, Naderi M, Dorgalaleh A. Intracranial hemorrhage in congenital bleeding disorders. Blood Coagul Fibrinolysis. 2018;29:1.
Greipp PR, Kyle RA, Bowie E. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol. 1981;11(4):443–50.
Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia. 2001;7(s1):16–22.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Roshanzamir, F., Dorgalaleh, A. (2018). Congenital Factor X Deficiency. In: Dorgalaleh, A. (eds) Congenital Bleeding Disorders . Springer, Cham. https://doi.org/10.1007/978-3-319-76723-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-76723-9_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-76722-2
Online ISBN: 978-3-319-76723-9
eBook Packages: MedicineMedicine (R0)